Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACE 232

Next Previous
Drug Profile

ACE 232

Alternative Names: ACE-232

Latest Information Update: 06 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Acerand Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cholesterol side chain cleavage enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 12 May 2025 Phase-I clinical trials in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in USA (PO) (NCT06801236)
  • 07 Feb 2025 Acerand Therapeutics plans a phase I trial for Prostate cancer (Hormone refractory, Combination therapy, Metastatic disease) in the US (PO, tablet) (NCT06801236)
  • 04 Feb 2025 Preclinical trials in Prostate cancer in China (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top